Electrophysiology

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Tuesday, February 23, 2021 - 6:33pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Tuesday, February 23, 2021 - 6:16pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

Rhythmlink Receives FDA Clearance for New MR Conditional Electrode Line

Tuesday, February 23, 2021 - 1:00pm

Rhythmlink International, LLC has announced FDA clearance of a new product line.

Key Points: 
  • Rhythmlink International, LLC has announced FDA clearance of a new product line.
  • Sticky Pad Surface Electrodes, a line of peel and stick-on electrodes for Intraoperative Neurophysiological Monitoring (IONM) and Electroencephalography (EEG) are now FDA Cleared MR Conditional for 1.5 and 3 Tesla MRI environments.
  • View the full release here: https://www.businesswire.com/news/home/20210223005148/en/
    MR Conditional Sticky Pads are specially designed for stimulating, recording or grounding.
  • Rhythmlinks original Sticky Pad Electrode line set a new industry benchmark as the only Sticky Pad Electrode to be cleared for both recording and stimulating.

Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Te

Wednesday, February 17, 2021 - 1:30pm

This same functional lab can be used to study consumer behavior and psychology in markets Ehave operates for further commercialization of Ehaves data and technologies.

Key Points: 
  • This same functional lab can be used to study consumer behavior and psychology in markets Ehave operates for further commercialization of Ehaves data and technologies.
  • Brain Scientific is seeking to improve neurology by modernizing the brain diagnostic market with its cutting-edge technology.
  • As part of the MoU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap and NeuroEEG, for the Ehave platform.
  • All data from any transactions contemplated by the MoU will be jointly owned by both Ehave and Brain Scientific.

Worldwide Bioelectric Medicine Industry to 2030 - Impact Analysis of COVID-19

Tuesday, February 16, 2021 - 1:00pm

The global bioelectric medicine market will reach $39.06 billion by 2030, growing by 6.4% annually over 2020-2030 driven by growing geriatric population and rising acceptance of bioelectric medicines.

Key Points: 
  • The global bioelectric medicine market will reach $39.06 billion by 2030, growing by 6.4% annually over 2020-2030 driven by growing geriatric population and rising acceptance of bioelectric medicines.
  • Bioelectric medicines, also known as electroceuticals, are medical devices that are used to restore health in patients.
  • This report is based on a comprehensive research of the entire global bioelectric medicine market and all its sub-segments through extensively detailed classifications.
  • Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

Global Bioelectric Medicine Market (2020 to 2030) - by Product Type, End-user, and Region - ResearchAndMarkets.com

Monday, February 15, 2021 - 12:29pm

The "Global Bioelectric Medicine Market 2020-2030 by Product Type (Implantable, Non-invasive), End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bioelectric Medicine Market 2020-2030 by Product Type (Implantable, Non-invasive), End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • The global bioelectric medicine market will reach $39.06 billion by 2030, growing by 6.4% annually over 2020-2030 driven by growing geriatric population and rising acceptance of bioelectric medicines.
  • Bioelectric medicines, also known as electroceuticals, are medical devices that are used to restore health in patients.
  • This report is based on a comprehensive research of the entire global bioelectric medicine market and all its sub-segments through extensively detailed classifications.

Ben-Gurion University Researchers Introduce New Method for Diagnosing Neurological and Psychiatric Conditions

Tuesday, February 9, 2021 - 9:00am

BEER-SHEVA, Israel, Feb. 9, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) have developed a new method for rapidly diagnosing brain blood vessel pathology that may lead to neurodegenerative diseases, such as Alzheimer's disease, as well as other neurological and psychiatric conditions, including epilepsy, traumatic brain injury and stroke.

Key Points: 
  • BEER-SHEVA, Israel, Feb. 9, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) have developed a new method for rapidly diagnosing brain blood vessel pathology that may lead to neurodegenerative diseases, such as Alzheimer's disease, as well as other neurological and psychiatric conditions, including epilepsy, traumatic brain injury and stroke.
  • The novel diagnostic method is based on findings from the lab of Prof. Friedman that patients with Alzheimer's disease and other brain conditions display nonconvulsive epileptic seizure-like activity that can be detected by EEG recordings.
  • "This new approach for diagnosing neurological conditions based on analysis of changes of blood vessels in the brain can be valuable for the early detection of Alzheimer's disease and other neurological conditions, at the stage when treatment can still slow down disease progression.
  • BGN Technologiesis the technology transfer companyof Ben-Gurion University, the third largest university in Israel.

B-Secur Receives FDA Regulatory Clearance For Its HeartKey® EKG/ECG Technology

Thursday, February 4, 2021 - 5:00pm

B-Secur , a leader in EKG/ECG technology, today announced that it has received U.S. Food and Drug Administration (FDA) 510(K) clearance of its HeartKey software library1.

Key Points: 
  • B-Secur , a leader in EKG/ECG technology, today announced that it has received U.S. Food and Drug Administration (FDA) 510(K) clearance of its HeartKey software library1.
  • This clearance should significantly aid our partners and customers increase the speed to market for their technology.
  • FDA clearance has been granted for the following EKG/ECG feature algorithms: Signal Conditioning, Heart Rate and Arrhythmia Analysis.
  • FDA clearance of the HeartKey software library ensures B-Secur customers and partners can have confidence in its world-leading algorithm performance and accuracy.

New Wearable ECG Recorder Gets FDA Clearance: Versatile Wearable Sensor offers Extended Ambulatory ECG Recording Up to 21 Days

Wednesday, February 3, 2021 - 2:00pm

MANLIUS, N.Y., Feb. 3, 2021 /PRNewswire-PRWeb/ -- Global Instrumentation, LLC, announced today the FDA has cleared the company's ultra-small wearable electrocardiogram (ECG) sensor, the M5 Recorder.

Key Points: 
  • MANLIUS, N.Y., Feb. 3, 2021 /PRNewswire-PRWeb/ -- Global Instrumentation, LLC, announced today the FDA has cleared the company's ultra-small wearable electrocardiogram (ECG) sensor, the M5 Recorder.
  • The device offers research organizations and physicians a reliable, shower-proof, and patient-friendly ECG sensor for precise long-term ECG data collection in the patient's home and ambulatory environments.
  • The M5 Recorder is water-resistant and weighs only 26 grams yet can store up to 21 days of 3-channel ECG recordings.
  • Through our proven research, design, and innovation capabilities, we partner closely with our customers to help enable the delivery of better healthcare.

Cardiac Insight Comments on Medicare Administrative Contractor Novitas Rate Publication

Monday, February 1, 2021 - 8:46pm

Cardiac Insight , Inc. a healthcare innovator specializing in wearable cardiac sensors and proven automated electrocardiogram (ECG) analysis that delivers highly differentiated benefits to healthcare providers and patients, commented on the recent reimbursement rates published by Medicare Administrative Contractor (MAC) Novitas Solutions (Novitas) for CPT codes 93241, 93243, 93245, and 93247.

Key Points: 
  • Cardiac Insight , Inc. a healthcare innovator specializing in wearable cardiac sensors and proven automated electrocardiogram (ECG) analysis that delivers highly differentiated benefits to healthcare providers and patients, commented on the recent reimbursement rates published by Medicare Administrative Contractor (MAC) Novitas Solutions (Novitas) for CPT codes 93241, 93243, 93245, and 93247.
  • Novitas provides administrative and claims processing services for state and federal health care programs such as Medicare and Medicaid and is owned by GuideWell.
  • This untenable decision significantly sets back patient care as it will limit access to extended ECG testing for patients and physicians nationwide, said Brad Harlow, CEO of Cardiac Insight.
  • ABOUT CARDIAC INSIGHT, INC: Cardiac Insight, Inc. ( www.cardiacinsightinc.com ) is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn ECG sensor technology and automated cardiac analysis solutions through its proprietary algorithms and software platforms.